1 suspended. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Suspended 1 |
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301 CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg - ADHD, ADHD - Combined Type | Phase 3 | Suspended | Cingulate Therapeutics | 45 | 2023-07-31 | 2026-05-05 |
Attention Deficit Disorder with Hyperactivity (1)
Mental Disorders (1) · Neurodevelopmental Disorders (1)
Dexmethylphenidate Hydrochloride (1)
United States (1)
Matt Brams, MD (1)